Sudeep Pharma eyes Rs. 895 crore fundraising from debut on bourses
The issue comprises a fresh issue of Rs. 95 crore and targeting a total raise of around Rs. 895 crore
The issue comprises a fresh issue of Rs. 95 crore and targeting a total raise of around Rs. 895 crore
Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
FDA closes inspection at Zydus' oncology injectable manufacturing facility in SEZ1, Ahmedabad with 2 observations
With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
Uncontrolled diabetes in pregnancy dramatically increases the risk of pre-eclampsia, stillbirth, birth injuries, and long-term cardiometabolic diseases
The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses
The offering is expected to close on November 10, 2025, subject to customary closing conditions
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
Subscribe To Our Newsletter & Stay Updated